DBV Technologies S.A. - Regulatory Filings 2017

6-K 1 d364294d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2017

Commission File Number: 001-36697

DBV TECHNOLOGIES S.A.

(Translation of registrants name into English)

177-181 avenue Pierre Brossolette

92120 Montrouge France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXHIBIT LIST

Exhibit	Description
99.1	Press Release dated May 2, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/s/ David Schilansky
Name	David Schilansky
Title:	Chief Operating Officer

Exhibit 99.1

Press Release

Montrouge, France, May 2, 2017

DBV Technologies to Attend Upcoming Investor Conferences

DBV Technologies (Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that members of its management team will present and host investor meetings at the following upcoming investor conferences:

Susanna Mesa, Senior Vice President, Strategy, will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, NV, on Wednesday, May 17, 2017, at 9:20 am PT.

Pierre-Henri Benhamou, Chairman & Chief Executive Officer, David Schilansky, Chief Operating Officer & Deputy Chief Executive Officer, and Sébastien Robitaille, Deputy Chief Financial Officer, will host investor meetings at the Gilbert Dupont 15 th Annual Healthcare Conference on Tuesday, May 30, 2017, in Paris, France.

Susanna Mesa, Senior Vice President, Strategy, will present at the Barclays West Coast Biopharma Conference in Calistoga, CA, on Thursday, June 1, 2017, at 10:30 am PT.

Pierre-Henri Benhamou, Chairman & Chief Executive Officer, and David Schilansky, Chief Operating Officer & Deputy Chief Executive Officer, will host investor meetings at the Société Générale 12 th Edition of the Nice Conference on Friday, June 2, 2017, in Nice, France.

A live webcast of the Bank of America Merrill Lynch 2017 Health Care Conference will be available on the Investor Relations section of the Companys website: http://www.dbv-technologies.com/en/investor-relations . A replay of the presentation will also be available on DBVs website within three hours after the event.

About DBV Technologies

DBV Technologies is developing Viaskin ® , a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT ® , DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

DBV Technologies Contact

Sara Blum Sherman

Director, Investor Relations

+1 212-271-0740

[email protected]

Media Contact

Andrea Fassacesia, Weber Shandwick

+1 212-445-8144

[email protected]

Media Contact Europe

Caroline Carmagnol, Alize RP, Relations Presse

+33 (0)6 64 18 99 59